KREBSBIO Q2 : STANDALONE NET LOSS NARROWS 12.1% AT ₹5.40 CR (YOY), WIDENS 117% (QOQ). MIX (On 1st Look)

Revenue up 38.9% at ₹5.79 Cr (YOY), down 17.1% (QOQ). Finance costs ₹1.90 Cr v ₹1.73 Cr (YOY); depreciation ₹1.61 Cr v ₹1.62 Cr (YOY). Caution: Vizag manufacturing unit continues to remain closed pursuant to APPCB order dated 7 Feb 2025; firm in talks for revocation. Board approved amalgamation of Krebs Biochemicals with Ipca Laboratories; appointed date 1 Apr 2026. Other equity turns positive at ₹19,219.86 lakh as at 30 Sep 2026 v negative ₹18,431.53 lakh on 31 Mar 2026.

Krebs Biochemicals & Industries Ltd-$

Open attachment

← Back to feed